Home > News > Clinical trials put dendrimers on course for treating HIV
September 24th, 2003
Clinical trials put dendrimers on course for treating HIV
They might be nano’s artificial molecule, but dendrimers are taking real steps toward fighting HIV and sexually transmitted diseases in women. Starpharma Pooled Development Ltd. of Melbourne, Australia, gained approval in July from the U.S. Food and Drug Administration to start human trials of VivaGel, a dendrimer-based topical gel designed to prevent or reduce disease transmission during sexual intercourse. It’s the first dendrimer – and defined nanostructure – cleared for clinical testing, according to John Raff, Starpharma’s chief executive.
Nanoscale assembly line August 29th, 2014
Copper shines as flexible conductor August 29th, 2014
Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices August 28th, 2014
PetLife Comments on CNN Story on Scorpion Venom Health Benefits August 27th, 2014